Special Issue

Topic: The Evolving Nomenclature of the Metabolic Fatty Liver Syndromes: NAFLD/NASH and MAFLD/MASLD

A Special Issue of Metabolism and Target Organ Damage

ISSN 2769-6375 (Online)

Submission deadline: 31 Jul 2024

Guest Editor(s)

Prof. Amedeo Lonardo
Department of Internal Medicine, Azienda Ospedaliero-Universitaria, Modena, Italy.

Special Issue Introduction

Over time, the nomenclature concerning "metabolic fatty liver syndromes" (MFLS), i.e., nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, and metabolic dysfunction-associated fatty liver disease/ metabolic dysfunction-associated steatotic liver disease (NAFLD/NASH and MAFLD/MASLD) has undergone multiple iterations, ranging from "fatty liver" to "fatty infiltration of the liver",  "hepatic steatosis",  "diabetic hepatitis",  "alcohol-like liver disease in the nonalcoholic", "bright liver syndrome", "metabolic fatty liver disorders", and  "metabolic fatty liver disease", among others.

Key milestones include the introduction of  "NASHby Ludwig et al. in 1980,  "NAFLDby Schaffner and Thaler in 1986,  "MAFLD" by Eslam et al. in 2020, and the recent addition of  "MASLD" by Rinella et al. in 2023.

Various factors, both medical and non-medical, have prompted these changes. Medical drivers seek to establish positive diagnostic criteria (metabolic dysfunction-associated) as opposed to negative ones (nonalcoholic). Non-medical factors aim to mitigate stigmatization linked with terms like  "nonalcoholic" and  "fatty", which can vary dramatically across cultures, geographical areas, and populations, partly leading to confusion among hepatologists.

Determining an optimal nomenclature for MFLS presents challenges. It should be easily intelligible by most people, support precision medicine approaches by categorizing homogenous subsets of patients with similar disease trajectories. Importantly, it should gain consensus among stakeholders such as patients, physicians, nurses, healthcare providers, policymakers, investigators, clinicians, and industries involved in the research of new drugs and the manufacturing of diagnostic tools and devices.

Advancement of science relies on the generation and analysis of new data, and defining nomenclature for MFLS is no exception. The capacity of each nomenclature to pinpoint specific patient populations and delineate diverse disease trajectories warrants empirical evaluation to weigh their merits and drawbacks.

Within this rapidly evolving scenario, the present Special Issue focuses on all types of contributions, including Letters to the Editor, Editorials, Comments, Perspectives, Original and Review articles pertaining to the various nomenclatures of MFLS: NAFLD/NASH, and MAFLD/MASLD. Additionally, investigations on stigma associated with the MFLS are also welcomed.

Submission Deadline

31 Jul 2024

Submission Information

For Author Instructions, please refer to https://www.oaepublish.com/mtod/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=mtod&SpecialIssueId=mtod240111
Submission Deadline: 31 Jul 2024
Contacts: Jennifer Lee, Assistant Editor, jennifer@mtodjournal.net

Published Articles

MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding metabolic syndrome?

Open Access Perspective DOI: 10.20517/mtod.2024.06 26 Feb 2024
Views: Downloads:
Download PDF
Metabolism and Target Organ Damage
ISSN 2769-6375 (Online)


All published articles are preserved here permanently:



All published articles are preserved here permanently: